Skip to main content
Medicamen Biotech Ltd. logo

Medicamen Biotech Ltd. — Investor Relations & Filings

Ticker · MEDICAMEQ ISIN · INE646B01010 LEI · 894500T0ULD27B7W4Y03 BSE.NS Manufacturing
Open in API
Filings indexed 277 across all filing types
Latest filing 2024-07-25 Regulatory Filings
Country IN India
Listing BSE.NS MEDICAMEQ

About Medicamen Biotech Ltd.

https://www.medicamen.com/

Medicamen Biotech Ltd. specializes in the research, development, and manufacturing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities compliant with international quality standards, including WHO-GMP. Its product portfolio encompasses various therapeutic segments such as oncology, cardiology, central nervous system, and anti-infectives, delivered through dosage forms like tablets, capsules, and liquid orals. A significant strategic focus is placed on its specialized oncology division, which develops complex generic formulations. The company serves global markets, leveraging its research and development capabilities to provide high-quality healthcare solutions. Its operations are supported by dedicated R&D centers focused on formulation development and process chemistry.

Recent filings

Filing Released Lang Actions
Resignation
Regulatory Filings
2024-07-25 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2024-07-11 English
Reply to Clarification- Financial results
Regulatory Filings
2024-07-10 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal notice from Medicamen Biotech Limited addressed to stock exchanges regarding the closure of the trading window for directors and designated persons. It specifies the trading window closure period around the announcement of unaudited financial results for the quarter ended June 30, 2024. The document does not contain any financial data or results itself, nor does it include a report or detailed financial statements. It is an announcement related to compliance with insider trading regulations and timing of trading restrictions. Given the short length (1674 characters) and the nature of the content, this is not a financial report or earnings release but a regulatory announcement about trading restrictions. Therefore, the appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-06-27 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a compliance notice under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing stock exchanges about the issuance of duplicate share certificates due to lost original certificates. It is an official regulatory announcement related to share certificate status, not a financial report, management change, or voting result. The document is short (1483 characters) and serves as a regulatory compliance filing. Therefore, it fits best under Regulatory Filings (RNS).
2024-06-05 English
Updates
Regulatory Filings Classification · 95% confidence The document is an announcement informing about the completion of an EU GMP inspection at a specific facility of Medicamen Biotech Limited. It references a regulatory inspection and the expected certification but does not contain financial data, management discussion, voting results, or any detailed report content. The document is short (1513 characters) and serves as a regulatory update to stock exchanges pursuant to SEBI regulations. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or others that require substantive financial or operational data. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2024-05-31 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.